Arcturus Therapeutics Holdings Inc.ARCTNASDAQ
Loading
R&D Expense Growth Recovery in ProgressRecovering
Percentile Rank62
5Y CAGR-32.5%
Year-over-Year Change
Year-over-year research & development expense growth
5Y CAGR
-32.5%/yr
Long-term compound
Percentile
P62
Within normal range
vs 5Y Ago
0.1x
Contraction
Streak
1 qtr
Consecutive growthRecovering
| Period | Value |
|---|---|
| Q4 2025 | 5.21% |
| Q3 2025 | -21.35% |
| Q2 2025 | -15.23% |
| Q1 2025 | -20.30% |
| Q4 2024 | 11.87% |
| Q3 2024 | -33.30% |
| Q2 2024 | 9.51% |
| Q1 2024 | 46.29% |
| Q4 2023 | -28.30% |
| Q3 2023 | -3.02% |
| Q2 2023 | 1.74% |
| Q1 2023 | 91.87% |
| Q4 2022 | -28.41% |
| Q3 2022 | -1.31% |
| Q2 2022 | -14.93% |
| Q1 2022 | 37.57% |
| Q4 2021 | -28.12% |
| Q3 2021 | -0.62% |
| Q2 2021 | -8.73% |
| Q1 2021 | 106.09% |
| Q4 2020 | 37.22% |
| Q3 2020 | 122.80% |
| Q2 2020 | 0.34% |
| Q1 2020 | -33.99% |
| Q4 2019 | 70.06% |
| Q3 2019 | -2.97% |
| Q2 2019 | -0.75% |
| Q1 2019 | 51.10% |
| Q4 2018 | 22.12% |
| Q3 2018 | -6.06% |
| Q2 2018 | 7.21% |
| Q1 2018 | -65.30% |
| Q4 2017 | 972.33% |
| Q3 2017 | -26.61% |
| Q2 2017 | -29.95% |
| Q1 2017 | -53.68% |
| Q4 2016 | -30.52% |
| Q3 2016 | 53.04% |
| Q2 2016 | 24.39% |
| Q1 2016 | 0.81% |